Rising Prevalence Of Hemoglobin Disorders Such As Sickle Cell Anemia, Thalassemia, Hb C, & Hb E Is Expected To Drive Hemoglobinopathies Market Till 2022:Grand View Research,Inc.
Global hemoglobinopathies market is expected to reach over USD 8.82
billion by 2022 according to a new report by Grand View Research Inc. Rising
prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb
C, and Hb E is estimated to be the high impact rendering drivers of the market.
According to the WHO, hemoglobin disorders are endemic in over 60% of 229
countries affecting over 70% of births. It is also reported that minimum 5% of
the world population are carriers of significant variation.
Prevalence of hemoglobinopathies
is high in low-income countries such as Sub Saharan region and South East Asia.
85% of the affected population in the U.S. and Europe has ancestral base in
these regions.
Governments are collaborating
with local institutes to undertake awareness programs for curbing the effect of
hemoglobinopathies-related mortality rate. For instance, Thalassemia Data
Collection Project and Registry and Surveillance System for Hemoglobinopathies
(RuSH) projects were started in 2010 by the Centers for Disease Control and
Prevention (CDC).
Low level of hygiene,
insufficient healthcare infrastructure, and lesser awareness levels are some
key factors attributing to increase in base of target population in low-income
regions such as South East Asia, Mediterranean basin, and Africa.
Browse full research report on Hemoglobinopathies Market: http://www.grandviewresearch.com/industry-analysis/hemoglobinopathies-market
Further key findings from the study suggest:
- The market for Sickle Cell Disease (SCD) was the
largest with revenue valued at over USD 2,290.0 million in 2014. Rising
prevalence of hemoglobinopathies and presence of strong product pipeline
for sickle cell anemia such as HQK-1001 and Luspatercept are growth
promoting factors of this market.
- Genetic testing for diagnosis of sickle cell
disorders is expected to witness lucrative growth over the forecast
period. It is estimated to grow at a CAGR of around 7.0%. Increasing
awareness levels among people coupled with government programs such as the
National Sickle Cell Disease Control Program conducted by the WHO in
Africa are anticipated to enhance the usage rates for diagnostic tests
pertaining to SCD.
- Hydroxyurea was one of the dominating segments of the
SCD therapy market owing to the presence of the FDA-approved drugs such as
Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market holds an
extensive product portfolio in pipeline and their expected
commercialization is anticipated to drive market growth. For instance, The
Ellis Lab is developing a gene therapy for SCD in collaboration with Dr.
Victor Garcia
- Blood tests including cell blood count and iron
studies are the widely used techniques for diagnosis of thalassemia. On
the other hand, pre-implant genetic testing is estimated to grow at
lucrative growth rate over 8.5% in the next six years owing to rising base
of health conscious population and increasing healthcare expenditure.
- The market for blood transfusion was the largest with
revenues valued at over USD 1,408.0 million in therapeutic segment owing
to, high acceptance level of this treatment option and significant success
rate. It is estimated that around 85% of infants below five years
suffering from thalassemia die due to insufficient blood transfusion.
- North America dominated the overall
hemoglobinopathies market in terms of revenue in 2014 at over USD 1,212.0
million. Growing prevalence of blood disorders, favorable government
programs, and high level of awareness among healthcare professionals and
patients for hemoglobinopathies-related genetic testing are factors
attributing to the major share of this market.
- Asia Pacific market is expected to witness lucrative
growth over the forecast period with a CAGR of over 10% owing to the
presence of high unmet clinical needs, improving healthcare
infrastructure, and rising economic levels. Moreover, introduction of
low-cost diagnostic alternatives will enhance adoption rates for
hemoglobinopathies diagnostics market.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the hemoglobinopathies market
on the basis of type, diagnostics, and therapeutics:
Global Hemoglobinopathies Therapy Outlook (Revenue, USD
Million), 2012 – 2022
- Thalassemia
- Alpha
thalassemia
- Beta
thalassemia
- Sickle
cell disease
- Hemoglobin
variants diseases
Global Hemoglobinopathies Diagnosis Outlook (Revenue, USD
Million), 2012 – 2022
- Thalassemia
- Alpha
thalassemia
- Beta
thalassemia
- Sickle
cell disease
- Hemoglobin
variants diseases
Hemoglobinopathies Regional Outlook (Revenue, USD
Million), 2012 – 2022
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
Access Press Release
By Grand View Research: http://www.grandviewresearch.com/press-release/global-hemoglobinopathies-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment